Circulating Hematopoietic Stem Cell Transplantation

Anne Kessinger, John G Sharp

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Circulating blood normally contains a subpopulation of self-renewing, pluripotent hematopoietic stem cells. The number of these cells in the circulation is usually quite low, but if they are increased deliberately with mobilizing therapies, they can be harvested efficiently in sufficient numbers for transplantation using apheresis techniques. Transplantation of mobilized hematopoietic stem cells, derived from the blood in both the autologous and allogeneic settings, provides faster marrow function recovery than transplantation of nonmobilized blood-derived stem cells or marrow-derived stem cells. Allogeneic transplants are performed if the recipient's marrow is malignant, as in myelogenous leukemia, and needs to be replaced or if a patient with genetic disorder, such as an immune deficiency, requires a new immune system generated from a new bone marrow for survival. Early studies of blood-derived stem-progenitor cell transplantation to lethally irradiated animal models were successful but clinical investigations required the development of techniques to collect the cells in large numbers, previously identified as necessary for successful marrow-derived hematopoietic stem cell transplantation. Five years passed before the next report of clinical attempts at blood-derived stem-progenitor cell transplantation using nonleukemic cells appeared. When the second marrow transplant also failed, collecting marrow from the donor a third time in a short period was problematic, so granulocyte colony-stimulating factor (G-CSF) was administered to this donor and mobilized blood stem cells were collected and infused.

Original languageEnglish (US)
Title of host publicationAdult and Fetal
PublisherElsevier Inc.
Pages685-693
Number of pages9
Volume2
ISBN (Electronic)9780080533735
ISBN (Print)9780124366435
DOIs
StatePublished - Sep 14 2004

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem cells
Bone Marrow
Blood
Stem Cells
Transplants
Stem Cell Transplantation
Transplantation
Tissue Donors
Pluripotent Stem Cells
Inborn Genetic Diseases
Blood Component Removal
Myeloid Leukemia
Recovery of Function
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cells
Immune system
Immune System
Blood Cells
Animal Models

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Kessinger, A., & Sharp, J. G. (2004). Circulating Hematopoietic Stem Cell Transplantation. In Adult and Fetal (Vol. 2, pp. 685-693). Elsevier Inc.. https://doi.org/10.1016/B978-012436643-5/50151-6

Circulating Hematopoietic Stem Cell Transplantation. / Kessinger, Anne; Sharp, John G.

Adult and Fetal. Vol. 2 Elsevier Inc., 2004. p. 685-693.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kessinger, A & Sharp, JG 2004, Circulating Hematopoietic Stem Cell Transplantation. in Adult and Fetal. vol. 2, Elsevier Inc., pp. 685-693. https://doi.org/10.1016/B978-012436643-5/50151-6
Kessinger A, Sharp JG. Circulating Hematopoietic Stem Cell Transplantation. In Adult and Fetal. Vol. 2. Elsevier Inc. 2004. p. 685-693 https://doi.org/10.1016/B978-012436643-5/50151-6
Kessinger, Anne ; Sharp, John G. / Circulating Hematopoietic Stem Cell Transplantation. Adult and Fetal. Vol. 2 Elsevier Inc., 2004. pp. 685-693
@inbook{212bcd936809404cb7aa590c1f5121ff,
title = "Circulating Hematopoietic Stem Cell Transplantation",
abstract = "Circulating blood normally contains a subpopulation of self-renewing, pluripotent hematopoietic stem cells. The number of these cells in the circulation is usually quite low, but if they are increased deliberately with mobilizing therapies, they can be harvested efficiently in sufficient numbers for transplantation using apheresis techniques. Transplantation of mobilized hematopoietic stem cells, derived from the blood in both the autologous and allogeneic settings, provides faster marrow function recovery than transplantation of nonmobilized blood-derived stem cells or marrow-derived stem cells. Allogeneic transplants are performed if the recipient's marrow is malignant, as in myelogenous leukemia, and needs to be replaced or if a patient with genetic disorder, such as an immune deficiency, requires a new immune system generated from a new bone marrow for survival. Early studies of blood-derived stem-progenitor cell transplantation to lethally irradiated animal models were successful but clinical investigations required the development of techniques to collect the cells in large numbers, previously identified as necessary for successful marrow-derived hematopoietic stem cell transplantation. Five years passed before the next report of clinical attempts at blood-derived stem-progenitor cell transplantation using nonleukemic cells appeared. When the second marrow transplant also failed, collecting marrow from the donor a third time in a short period was problematic, so granulocyte colony-stimulating factor (G-CSF) was administered to this donor and mobilized blood stem cells were collected and infused.",
author = "Anne Kessinger and Sharp, {John G}",
year = "2004",
month = "9",
day = "14",
doi = "10.1016/B978-012436643-5/50151-6",
language = "English (US)",
isbn = "9780124366435",
volume = "2",
pages = "685--693",
booktitle = "Adult and Fetal",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Circulating Hematopoietic Stem Cell Transplantation

AU - Kessinger, Anne

AU - Sharp, John G

PY - 2004/9/14

Y1 - 2004/9/14

N2 - Circulating blood normally contains a subpopulation of self-renewing, pluripotent hematopoietic stem cells. The number of these cells in the circulation is usually quite low, but if they are increased deliberately with mobilizing therapies, they can be harvested efficiently in sufficient numbers for transplantation using apheresis techniques. Transplantation of mobilized hematopoietic stem cells, derived from the blood in both the autologous and allogeneic settings, provides faster marrow function recovery than transplantation of nonmobilized blood-derived stem cells or marrow-derived stem cells. Allogeneic transplants are performed if the recipient's marrow is malignant, as in myelogenous leukemia, and needs to be replaced or if a patient with genetic disorder, such as an immune deficiency, requires a new immune system generated from a new bone marrow for survival. Early studies of blood-derived stem-progenitor cell transplantation to lethally irradiated animal models were successful but clinical investigations required the development of techniques to collect the cells in large numbers, previously identified as necessary for successful marrow-derived hematopoietic stem cell transplantation. Five years passed before the next report of clinical attempts at blood-derived stem-progenitor cell transplantation using nonleukemic cells appeared. When the second marrow transplant also failed, collecting marrow from the donor a third time in a short period was problematic, so granulocyte colony-stimulating factor (G-CSF) was administered to this donor and mobilized blood stem cells were collected and infused.

AB - Circulating blood normally contains a subpopulation of self-renewing, pluripotent hematopoietic stem cells. The number of these cells in the circulation is usually quite low, but if they are increased deliberately with mobilizing therapies, they can be harvested efficiently in sufficient numbers for transplantation using apheresis techniques. Transplantation of mobilized hematopoietic stem cells, derived from the blood in both the autologous and allogeneic settings, provides faster marrow function recovery than transplantation of nonmobilized blood-derived stem cells or marrow-derived stem cells. Allogeneic transplants are performed if the recipient's marrow is malignant, as in myelogenous leukemia, and needs to be replaced or if a patient with genetic disorder, such as an immune deficiency, requires a new immune system generated from a new bone marrow for survival. Early studies of blood-derived stem-progenitor cell transplantation to lethally irradiated animal models were successful but clinical investigations required the development of techniques to collect the cells in large numbers, previously identified as necessary for successful marrow-derived hematopoietic stem cell transplantation. Five years passed before the next report of clinical attempts at blood-derived stem-progenitor cell transplantation using nonleukemic cells appeared. When the second marrow transplant also failed, collecting marrow from the donor a third time in a short period was problematic, so granulocyte colony-stimulating factor (G-CSF) was administered to this donor and mobilized blood stem cells were collected and infused.

UR - http://www.scopus.com/inward/record.url?scp=34447271077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447271077&partnerID=8YFLogxK

U2 - 10.1016/B978-012436643-5/50151-6

DO - 10.1016/B978-012436643-5/50151-6

M3 - Chapter

AN - SCOPUS:34447271077

SN - 9780124366435

VL - 2

SP - 685

EP - 693

BT - Adult and Fetal

PB - Elsevier Inc.

ER -